| UniProt ID | LRWD1_HUMAN | |
|---|---|---|
| UniProt AC | Q9UFC0 | |
| Protein Name | Leucine-rich repeat and WD repeat-containing protein 1 | |
| Gene Name | LRWD1 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 647 | |
| Subcellular Localization | Nucleus. Chromosome, centromere. Chromosome, telomere. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome . Chromosome, centromere, kinetochore . Localizes to heterochromatin during G1 phase. Restricted to centromeres or telomeres as | |
| Protein Description | Required for G1/S transition. Recruits and stabilizes the origin recognition complex (ORC) onto chromatin during G1 to establish pre-replication complex (preRC) and to heterochromatic sites in post-replicated cells. Binds a combination of DNA and histone methylation repressive marks on heterochromatin. Binds histone H3 and H4 trimethylation marks H3K9me3, H3K27me3 and H4K20me3 in a cooperative manner with DNA methylation. Required for silencing of major satellite repeats. May be important ORC2, ORC3 and ORC4 stability.. | |
| Protein Sequence | MGPLSARLLMQRGRPKSDRLGKIRSLDLSGLELLSEHLDPKLLCRLTQLQELDLSNNHLETLPDNLGLSHLRVLRCANNQLGDVTALCQFPKLEELSLEGNPFLTVNDNLKVSFLLPTLRKVNGKDASSTYSQVENLNRELTSRVTAHWEKFMATLGPEEEAEKAQADFVKSAVRDVRYGPESLSEFTQWRVRMISEELVAASRTQVQKANSPEKPPEAGAAHKPRARLAALKRPDDVPLSLSPSKRACASPSAQVEGSPVAGSDGSQPAVKLEPLHFLQCHSKNNSPQDLETQLWACAFEPAWEEGATSQTVATCGGEAVCVIDCQTGIVLHKYKAPGEEFFSVAWTALMVVTQAGHKKRWSVLAAAGLRGLVRLLHVRAGFCCGVIRAHKKAIATLCFSPAHETHLFTASYDKRIILWDIGVPNQDYEFQASQLLTLDTTSIPLRLCPVASCPDARLLAGCEGGCCCWDVRLDQPQKRRVCEVEFVFSEGSEASGRRVDGLAFVNEDIVASKGSGLGTICLWSWRQTWGGRGSQSTVAVVVLARLQWSSTELAYFSLSACPDKGIVLCGDEEGNVWLYDVSNILKQPPLLPAALQAPTQILKWPQPWALGQVVTKTMVNTVVANASFTYLTALTDSNIVAIWGRM | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 17 | Phosphorylation | MQRGRPKSDRLGKIR HHCCCCCCCCCCCCE | 30.55 | 22817900 | |
| 25 | Phosphorylation | DRLGKIRSLDLSGLE CCCCCCEECCCCHHH | 29.70 | 27732954 | |
| 29 | Phosphorylation | KIRSLDLSGLELLSE CCEECCCCHHHHHHH | 40.78 | 22115753 | |
| 41 | Ubiquitination | LSEHLDPKLLCRLTQ HHHCCCHHHHHHHHH | 54.48 | - | |
| 55 | Phosphorylation | QLQELDLSNNHLETL HHHCCCCCCCCHHCC | 34.94 | 27174698 | |
| 61 | Phosphorylation | LSNNHLETLPDNLGL CCCCCHHCCCCCCCC | 50.37 | 27174698 | |
| 69 | Phosphorylation | LPDNLGLSHLRVLRC CCCCCCCHHHHHHHC | 20.76 | 27174698 | |
| 121 | Ubiquitination | FLLPTLRKVNGKDAS EEHHHHEECCCCCCC | 43.07 | - | |
| 125 | Ubiquitination | TLRKVNGKDASSTYS HHEECCCCCCCCHHH | 44.94 | - | |
| 130 | Phosphorylation | NGKDASSTYSQVENL CCCCCCCHHHHHHHH | 25.38 | 22210691 | |
| 142 | Phosphorylation | ENLNRELTSRVTAHW HHHCHHHHHHHHHHH | 15.10 | 22210691 | |
| 146 | Phosphorylation | RELTSRVTAHWEKFM HHHHHHHHHHHHHHH | 16.22 | 22210691 | |
| 151 | Ubiquitination | RVTAHWEKFMATLGP HHHHHHHHHHHHHCC | 34.94 | - | |
| 171 | Ubiquitination | KAQADFVKSAVRDVR HHHHHHHHHHHHHHH | 32.46 | - | |
| 183 | Phosphorylation | DVRYGPESLSEFTQW HHHCCCCCHHHHHHH | 40.09 | 27067055 | |
| 196 | Phosphorylation | QWRVRMISEELVAAS HHHHHHHHHHHHHHH | 18.71 | 20860994 | |
| 205 | Phosphorylation | ELVAASRTQVQKANS HHHHHHHHHHHHCCC | 30.51 | 24732914 | |
| 212 | Phosphorylation | TQVQKANSPEKPPEA HHHHHCCCCCCCCCC | 39.02 | 29255136 | |
| 224 | Ubiquitination | PEAGAAHKPRARLAA CCCCCCCCHHHHHHH | 31.32 | - | |
| 233 | Acetylation | RARLAALKRPDDVPL HHHHHHHCCCCCCCC | 58.10 | 25953088 | |
| 241 | Phosphorylation | RPDDVPLSLSPSKRA CCCCCCCCCCCCCCC | 22.26 | 22167270 | |
| 243 | Phosphorylation | DDVPLSLSPSKRACA CCCCCCCCCCCCCCC | 24.61 | 29255136 | |
| 245 | Phosphorylation | VPLSLSPSKRACASP CCCCCCCCCCCCCCC | 31.25 | 22167270 | |
| 246 | Ubiquitination | PLSLSPSKRACASPS CCCCCCCCCCCCCCC | 47.61 | - | |
| 246 | Acetylation | PLSLSPSKRACASPS CCCCCCCCCCCCCCC | 47.61 | 25953088 | |
| 251 | Phosphorylation | PSKRACASPSAQVEG CCCCCCCCCCCEECC | 21.19 | 19664994 | |
| 253 | Phosphorylation | KRACASPSAQVEGSP CCCCCCCCCEECCCC | 28.92 | 29255136 | |
| 259 | Phosphorylation | PSAQVEGSPVAGSDG CCCEECCCCCCCCCC | 11.60 | 29255136 | |
| 264 | Phosphorylation | EGSPVAGSDGSQPAV CCCCCCCCCCCCCCE | 29.12 | 29255136 | |
| 267 | Phosphorylation | PVAGSDGSQPAVKLE CCCCCCCCCCCEEEC | 37.67 | 17525332 | |
| 283 | Phosphorylation | LHFLQCHSKNNSPQD CEEEECCCCCCCHHH | 44.71 | 26552605 | |
| 328 | Phosphorylation | VCVIDCQTGIVLHKY EEEEECCCCEEEEEC | 34.90 | - | |
| 335 | Phosphorylation | TGIVLHKYKAPGEEF CCEEEEECCCCCHHH | 11.13 | - | |
| 443 | Phosphorylation | LLTLDTTSIPLRLCP CEEECCCCCCCCCCC | 25.05 | 24719451 | |
| 628 | Phosphorylation | NTVVANASFTYLTAL HHHHHCCEEEEEEEC | 20.23 | 26853621 |
| Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
|---|---|---|---|---|---|---|
Oops, there are no upstream regulatory protein records of LRWD1_HUMAN !! | ||||||
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of LRWD1_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of LRWD1_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| ORC2_HUMAN | ORC2 | physical | 22935713 | |
| CUL4A_HUMAN | CUL4A | physical | 22935713 | |
| DDB1_HUMAN | DDB1 | physical | 22935713 | |
| ORC2_HUMAN | ORC2 | physical | 22939629 | |
| ORC3_HUMAN | ORC3 | physical | 22939629 | |
| ORC5_HUMAN | ORC5 | physical | 22939629 | |
| ADDA_HUMAN | ADD1 | physical | 26496610 | |
| ORC1_HUMAN | ORC1 | physical | 26496610 | |
| ORC2_HUMAN | ORC2 | physical | 26496610 | |
| ORC4_HUMAN | ORC4 | physical | 26496610 | |
| ORC5_HUMAN | ORC5 | physical | 26496610 | |
| TBG1_HUMAN | TUBG1 | physical | 26496610 | |
| GCP3_HUMAN | TUBGCP3 | physical | 26496610 | |
| GCP2_HUMAN | TUBGCP2 | physical | 26496610 | |
| ORC3_HUMAN | ORC3 | physical | 26496610 | |
| PRR3_HUMAN | PRR3 | physical | 26496610 | |
| GCP6_HUMAN | TUBGCP6 | physical | 26496610 | |
| MZT2A_HUMAN | MZT2A | physical | 26496610 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...
| Phosphorylation | |
| Reference | PubMed |
| "Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-212; SER-243 ANDSER-259, AND MASS SPECTROMETRY. | |
| "Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-251; SER-253 ANDSER-259, AND MASS SPECTROMETRY. | |
| "A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-212; SER-243; SER-251AND SER-259, AND MASS SPECTROMETRY. | |
| "Combining protein-based IMAC, peptide-based IMAC, and MudPIT forefficient phosphoproteomic analysis."; Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,Yates J.R. III; J. Proteome Res. 7:1346-1351(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-243; SER-245; SER-251AND SER-259, AND MASS SPECTROMETRY. | |
| "ATM and ATR substrate analysis reveals extensive protein networksresponsive to DNA damage."; Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.; Science 316:1160-1166(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-251 AND SER-267, ANDMASS SPECTROMETRY. | |
| "Improved titanium dioxide enrichment of phosphopeptides from HeLacells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra."; Yu L.-R., Zhu Z., Chan K.C., Issaq H.J., Dimitrov D.S., Veenstra T.D.; J. Proteome Res. 6:4150-4162(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-243, AND MASSSPECTROMETRY. | |
| "Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-212 AND SER-243, ANDMASS SPECTROMETRY. | |